Is Stoke Therapeutics, Inc. (STOK) a Buy, Sell, or Hold?
Stoke Therapeutics, Inc.
NASDAQ:STOK
$29.13 USD
-$0.33 (-1.12%)
- Volume
- 560.3K
- Average Volume
- 709.65K
- Market Capitalization
- $1.81B
- P/E Ratio
- -10.29
- Dividend Yield
- 0.00%
- Price Target
- $44.00
- Year High
- $40.22
- Year Low
- $11.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.99
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ian F. Smith |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | STOK |
| CUSIP | 86150R107 |
| CIK | 0001623526 |
| Web | https://www.stoketherapeutics.com |
| Phone | 781 430 8200 |
| Currency | USD |
| Employees | 170 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.99 |
| Quick Ratio | 8.99 |
| Cash Ratio | 3.81 |
Sales & Book Value
| Annual Sales | $184.42M |
| Price / Sales | 56.55 |
| Cash Flow | -2.34 |
| Price / Cash Flow | -12.28 |
| Price / Book | 4.65 |
Price Target and Rating
| Average Stock Price Forecast | $44.00 |
| High Stock Price Forecast | $60.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -33.80% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.12 |
| Trailing P/E Ratio | -10.29 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-6.88M |
| Net Margin | -529.20% |
| Pretax Margin | -533.18% |
| Return on Equity | -48.84% |
| Return on Assets | -38.30% |
Financials Score
| AltmanZ Score | 20.72 |
| Piotroski Score | 2.00 |
| Working Capital | 325.88M |
| Total Assets | 443.28M |
| Ebit | -167.64M |
| Market Cap | 1.83B |
| Total Liabilities | 48.4M |
Poll Results
About Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Phar ... maceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
2026-06-30 08:00:00
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolling.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-16 16:01:00
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 15, 2026, it granted stock options to purchase an aggregate of 103,020 shares of common stock to nine n.
2026-06-08 13:18:32
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4 Biotech Stocks Investors Should Watch in 2026
2026-06-05 11:55:27
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-06-04 10:56:09
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
2026-05-28 16:01:00
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
2026-05-21 12:27:23
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-05-18 16:01:00
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight n.
Frequently Asked Questions
-
What is the current Stoke Therapeutics, Inc. (STOK) stock price?
-
Stoke Therapeutics, Inc.(NASDAQ:STOK) stock price is $29.13 in the last trading session. During the trading session, STOK stock reached the peak price of $40.22 while $11.662 was the lowest point it dropped to. The percentage change in STOK stock occurred in the recent session was --1.12% while the dollar amount for the price change in STOK stock was -$-0.33.
-
STOK's industry and sector of operation?
-
The NASDAQ listed STOK is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of STOK?
-
Doug Snow | Director of Communications & Investor Relations
Adrian R. Krainer | Co-Founder & Independent Director
Edward Kaye | Advisor & Director
Jonathan Allan | Corporate Secretary & General Counsel
Isabel Aznarez | Co-Founder, Head of Research & Senior Vice President -
How many employees does STOK have?
-
Number of STOK employees currently stands at 170. STOK operates from 45 Wiggins Avenue, Bedford, MA 01730, US.
-
Link for STOK official website?
-
Official Website of STOK is: https://www.stoketherapeutics.com
-
How do I contact STOK?
-
STOK could be contacted at phone #781 430 8200 and can also be accessed through its website. STOK operates from 45 Wiggins Avenue, Bedford, MA 01730, US.
-
How many shares of STOK are traded daily?
-
The average number of STOK shares traded daily for last 3 months was 709.65K.
-
What is the market cap of STOK currently?
-
The market value of STOK currently stands at $1.81B with its latest stock price at $29.13